Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Core Insights - Pharma Two B presented integrated safety and efficacy data for P2B001, a combination drug for early-stage Parkinson's disease, at the Parkinson's Study Group Annual Meeting [1][2] - P2B001 is a once-daily, low-dose extended-release combination of pramipexole (0.6 mg) and rasagiline (0.75 mg) [1][7] - The data supports P2B001 as a potential first-line treatment option for early Parkinson's disease patients [2][3] Efficacy and Safety Data - P2B001 showed significant improvement in Unified Parkinson's Disease Rating Scale (UPDRS) scores, particularly in Activities of Daily Living (Part II) and Motor (Part III) compared to placebo [2] - The efficacy of P2B001 was comparable to individually titrated pramipexole ER (PramiER) [2] - P2B001 resulted in less daytime sleepiness and fewer sleep-related adverse events compared to PramiER [2] Company Developments - Pharma Two B is focused on completing a merger with Hepion Pharmaceuticals, which is expected to close in Q4 2024 [3][5] - The merger has been approved by both companies' boards and is subject to stockholder and regulatory approvals [5] - Following the merger, Pharma Two B plans to submit a New Drug Application (NDA) for P2B001 [3] Product Information - P2B001 is designed for early-stage Parkinson's disease and aims to improve patient quality of life with a favorable safety profile [4][7] - The drug combines previously approved oral medications, offering potential clinical benefits and enhanced convenience [4][8] - Pharma Two B holds worldwide patents for P2B001's composition and treatment method [8]